Geneva Advisors’s Idexx Laboratories IDXX Stock Holding History

Geneva Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$68.2M	Sell	422,799 -3,023	-0.7%	-$491K	1.18%	28
2017 Q1	$65.8M	Sell	425,822 -130,748	-23%	-$18M	1.18%	27
2016 Q4	$65.3M	Sell	556,570 -21,989	-4%	-$2.51M	1.27%	20
2016 Q3	$65.2M	Buy	578,559 +65,199	+13%	+$6.87M	1.23%	27
2016 Q2	$47.7M	Buy	513,360 +11,135	+2%	+$956K	0.94%	36
2016 Q1	$39.3M	Buy	502,225 +4,951	+1%	+$357K	0.79%	48
2015 Q4	$36.3M	Buy	497,274 +4,359	+0.9%	+$311K	0.7%	51
2015 Q3	$36.6M	Buy	492,915 +12,137	+3%	+$869K	0.74%	45
2015 Q2	$30.8M	Sell	480,778 -1,992	-0.4%	-$138K	0.55%	62
2015 Q1	$37.3M	Sell	482,770 -5,880	-1%	-$458K	0.67%	52
2014 Q4	$36.2M	Buy	+488,650	New	+$34.3M	0.67%	58

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Geneva Advisors's IDXX Position: Q2 2017 in Review

Geneva Advisors reduced its Idexx Laboratories (IDXX) stake by 0.71% in Q2 2017, selling an estimated $491K and leaving 422,799 shares worth $68.2M. The position accounts for 1.18% of the portfolio, ranked #28.

Geneva Advisors first reported a position in IDXX in Q4 2014 and has held it in 11 quarters since. 582 funds tracked by Wall St. Rank hold IDXX as of Q2 2017.

Geneva Advisors held 422,799 shares of Idexx Laboratories worth $68.2M as of Q2 2017.
Geneva Advisors sold 3,023 Idexx Laboratories shares in Q2 2017, an estimated $491K.
Idexx Laboratories made up 1.18% of Geneva Advisors's portfolio in Q2 2017, its #28 holding.
Geneva Advisors first reported a position in Idexx Laboratories in Q4 2014 and has held it in 11 quarters since.
582 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2017.

Based on Geneva Advisors's 13F filing for Q2 2017, filed 7 Aug 2017.